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Abstract
Background: Low pulse pressure predicts long-term mortality in chronic heart failure, but its prognostic value in acute
heart failure is less understood. The present study was designed to examine the prognostic value of pulse pressure in
acute heart failure.
Methods: Pulse pressure was tested for its impact on short- and long-term mortality in all patients admitted with acute
heart failure from October 2009 to December 2010 in eighteen tertiary centers in Saudi Arabia (n ¼ 2609). All comparisons were based on the median value (50 mmHg). Heart failure with reduced ejection fraction was deﬁned as less
than 40%.
Results: Low pulse pressure was associated with increased short-term mortality in the overall population (OR ¼ 1.61; 95
CI 1.17, 2.22; P 0.004 and OR ¼ 1.51; 95% CI 1.13, 2.01; P ¼ 0.005, for hospital and thirty-day mortality, respectively), and
short-term and two-year mortality in the reduced ejection fraction group (OR ¼ 1.81; 95% CI 1.19, 2.74; P ¼ 0.005,
OR ¼ 1.69; 95% CI 1.17, 2.45; P ¼ 0.006, and OR ¼ 1.29; 95% CI 1.02, 1.61; P ¼ 0.030 for hospital, thirty-day, and two-year
mortality, respectively). This effect remained after adjustment for relevant clinical variables; however, pulse pressure
lost its predictive power both for short-term and long-term mortality after the incorporation of systolic blood pressure in
the model. Conversely, low pulse pressure was an independent predictor of improved survival at two and three years in
heart failure with preserved ejection fraction (OR ¼ 0.43; 95% CI 0.24, 0.78, P ¼ 0.005 and OR ¼ 0.49; 95% CI 0.28, 0.88;
P ¼ 0.016, respectively).
Conclusion: In acute heart failure with reduced ejection fraction, the prognostic value of low pulse pressure was
dependent on systolic blood pressure. However, it inversely correlated with long-term survival in heart failure with
preserved ejection fraction.
Keywords: Acute heart failure, Pulse pressure, Mortality, Saudi Arabia
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1. Introduction

P

ulse pressure (PP) is a blood pressure (BP)
component that measures the pulsatility dynamics of the left ventricle (LV) throughout the
cardiac cycle, and is inﬂuenced by two main parameters: stroke volume and aortic elasticity
[1],[2]. In the Framingham study, elevated baseline PP carried a signiﬁcant future risk for coronary artery disease [3] and heart failure (HF) [4].
In addition, it independently predicted an overall
cardiovascular-related mortality in several studied populations [5e7].
The prognostication of PP across the spectrum of HF
syndromes is variable. In chronic symptomatic HF
with reduced ejection fraction (HFrEF), low PP was
predictive of all-cause mortality [8e12]. A similar
observation was found in HFrEF following acute coronary syndromes [13],[14]. However, post-hoc analyses from two recognized randomized trials revealed
a reverse pattern in asymptomatic HFrEF [15],[16].
Moreover, PP in HF with preserved EF (HFpEF) is less
understood owing to the lack of reports. Available
evidence emerges from three large-scale registries
with variable conclusions, where direct [9], U-shaped
[11], and neutral [8] relationships with long-term
survival were described.
Few reports have focused on PP and mortality rates
following an acute HF (AHF) hospitalization, and as
such, independent inverse relationships between PP
and extended mortality rates were described, especially in HFrEF [9],[11],[17]. All evidence about PP in
HF seems to emphasize on extended survival rates,
and there remains a literature gap on the clinical
utility of admission PP for predicting hospital mortality. The aim of this study is to examine the prognostic value of PP on short- and long-term outcomes
in both phenotypes of AHF, using data from the Heart
Function Assessment Registry Trial in Saudi Arabia
(HEARTS). We hypothesized that low PP will be
associated increased mortality in patients presenting
with AHF.

Abbreviations
AHF
BP
DBP
EF
HF
HF
HFrEF
HEARTS
LV
OR
PP
SBP

Acute Heart Failure
Blood Pressure
Diastolic Blood Pressure
Ejection Fraction
Heart Failure
Heart Failure with Preserved Ejection Fraction
Heart Failure with Reduced Ejection Fraction
Heart Function Assessment Registry Trial in
Saudi Arabia
Left Ventricle
Odds Ratio
Pulse Pressure
Systolic Blood Pressure

through January 2013. The deﬁnition of HF was
based on the European Society of Cardiology
guidelines for the diagnosis and treatment of acute
and chronic HF [20]. The study was approved by the
institutional review board at each participating
hospital and complied with the Declaration of Helsinki. An informed written consent was obtained
from all enrolled subjects.
BP was recorded on the ﬁrst encounter in the
emergency department. Measurements were done
over the brachial artery with standard automated
oscillometric devices or manual sphygmomanometers, depending on the practice of the participating
institution. PP was calculated as the difference between systolic BP (SBP) and diastolic BP (DBP).
Comparisons were assessed according to the PP
median value (50 mmHg). LV systolic function was
reported in categorical values as either normal
(50%) or reduced (mild; 40e49%, moderate;
30e39%, and severe; < 30%), with the cutoff deﬁnition for HFrEF as 40%. We described patients’
baseline characteristics, therapies, hospital course,
and hospital outcomes. The primary endpoints were
hospital, thirty-day, one-, two-, and three-year
mortality. We obtained the vital status following
hospital discharge by telephone interview, and then
veriﬁed these data as needed with the use of hospital records.

2. Methods

2.1. Statistical Analysis

The HEARTS protocol had been previously
described [18],[19]. Brieﬂy, HEARTS is a prospective
registry that enrolled 2609 consecutive patients aged
18 years and above with a primary admission
diagnosis of AHF. Eighteen tertiary care centers in
different regions of Saudi Arabia participated in this
registry. Enrollment took place between October
2009 and December 2010, with clinical follow-up

Categorical data were summarized with absolute
numbers and percentages. Numeric data were
summarized with mean and standard deviation or
the median and interquartile range. Comparisons
between the groups were performed using the Chisquare test or Fisher's exact test for categorical
variables and the independent sample T-test or
ManneWhitney U test for continuous variables. We

Table 1. Baseline characteristics of all acute heart failure patients based on pulse pressure median value.

Demographics
Age, mean ± SD
Male, n (%)
Body mass index, mean ± SD
Risk factors
Diabetes mellitus, n (%)
Smoker/Ex-smoker, n (%)
Hypertension, n (%)
Dyslipidemia, n (%)
History of cardiovascular diseases
Heart failure, n (%)
Ischemic heart disease, n (%)
Percutaneous coronary intervention, n (%)
Coronary artery bypass graft, n (%)
Rheumatic heart disease, n (%)
Other valvular heart disease, n (%)
Atrial ﬁbrillation, n (%)
Ventricular arrhythmias, n (%)
Implantable cardioverter deﬁbrillator, n (%)
Cardiac resynchronization therapy, n (%)
Transient ischemic attack/stroke, n (%)
Peripheral arterial disease, n (%)
History of other chronic medical illnesses
Anemia, n (%)
Chronic renal insufﬁciency, n (%)
Chronic lung disease, n (%)

Total,
2609

PP  50,
1360 (52.1%)

PP > 50,
1249 (47.9%)

P-value

61.3 ± 14.9
1717 (65.8)
29.2 ± 6.7

58.5 ± 16.1
1002 (73.7)
28.2 ± 6.0

64.4 ± 13.1
715 (57.2)
30.2 ± 7.4

<0.001
<0.001
<0.001

1668 (64.1)
872 (33.4)
1831 (70.6)
894 (36.4)

754
537
791
375

914 (73.3)
335 (26.8)
1040 (83.7)
519 (44.5)

<0.001
<0.001
<0.001
<0.001

1670 (64.2)
1376 (53.3)
340 (13.1)
261 (10.0)
183 (7.1)
390 (15.0)
408 (15.7)
64 (2.5)
229 (8.8)
85 (3.3)
252 (9.7)
99 (3.8)

900 (66.3)
677 (50.3)
177 (13.0)
134 (9.9)
111 (8.2)
227 (16.7)
223 (16.5)
48 (3.5)
166 (12.2)
62 (4.5)
111 (8.2)
45 (3.3)

770 (62.0)
699 (56.5)
163 (13.1)
127 (10.2)
72 (5.8)
163 (13.2)
185 (14.9)
16 (1.3)
63 (5.1)
23 (1.9)
141 (11.3)
54 (4.4)

0.021
0.002
0.965
0.792
0.016
0.010
0.267
<0.001
<0.001
<0.001
0.007
0.170

1166 (44.9)
771 (29.7)
185 (7.1)

558 (41.2)
359 (26.5)
82 (6.0)

608 (49.1)
412 (33.2)
103 (8.3)

<0.001
<0.001
0.027

(55.7)
(39.5)
(58.6)
(29.1)

for the overall population and repeated separately
for each HF phenotype (EF < 40% vs. EF  40%).
The KaplaneMeier analysis was applied to plot the
cumulative survival and differences between curves
were assessed by the log-rank test. A two-sided Pvalue of <0.05 was considered statistically signiﬁcant. All analyses were performed using [SAS/
STAT] software, Version [9.2] (SAS Institute Inc.,
Cary, NC, USA.) and (R Foundation for Statistical
Computing, Vienna, Austria).

used logistic regression models to estimate unadjusted and adjusted odds ratios (OR) for primary
endpoints. We adjusted for age, gender, body mass
index, diabetes mellitus, smoking, hypertension,
dyslipidemia, history of HF, anemia, HF etiology,
heart rate, and estimated glomerular ﬁltration rate.
Further, we applied stepwise adjustment by introducing BP components (SBP and DBP) to the
models to test their effect on the predictive power of
PP. Our multivariate analysis was done collectively

Table 2. Etiologies and exacerbation factors of all acute heart failure patients based on pulse pressure median value.

Heart failure etiology
Ischemic heart disease, n (%)
Idiopathic dilated cardiomyopathy, n (%)
Hypertensive heart disease, n (%)
Primary valvular heart disease, n (%)
Other etiologies, n (%)
Decompensated heart failure exacerbation factors
ST elevation myocardial infarction, n (%)
Non-ST elevation acute coronary syndromes, n (%)
Dietary noncompliance, n (%)
Noncompliance to HF medications, n (%)
Infections, n (%)
Uncontrolled hypertension, n (%)
Worsening renal failure, n (%)
Arrhythmia, n (%)
Lung disease exacerbation, n (%)

Total,
2609

PP  50,
1360 (52.1%)

PP > 50,
1249 (47.9%)

P-value

1454 (55.7)
431 (16.5)
307 (11.8)
202 (7.7)
215 (8.3)

779 (57.3)
295 (21.7)
52 (3.8)
116 (8.5)
118 (8.7)

675 (54.0)
136 (10.9)
255 (20.4)
86 (6.9)
97 (7.8)

<0.001

276
711
659
549
537
516
457
284
101

164 (12.1)
355 (26.1)
387 (28.5)
323 (23.8)
271 (19.9)
77 (5.7)
234 (17.2)
165 (12.1)
37 (2.7)

112 (9.0)
356 (28.5)
272 (21.8)
226 (18.1)
266 (21.3)
439 (35.2)
223 (17.9)
119 (9.5)
64 (5.1)

0.010
0.169
<0.001
<0.001
0.387
<0.001
0.663
0.033
0.001

(10.6)
(27.3)
(25.3)
(21.0)
(20.6)
(19.8)
(17.5)
(10.9)
(3.9)
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Table 3. Clinical presentation and investigations of all acute heart failure patients based on pulse pressure median value.

Hemodynamic parameters
Systolic blood pressure, mean ± SD
Diastolic blood pressure, mean ± SD
Heart rate, mean ± SD
Electrocardiography
Wide QRS duration, n (%)
Left bundle branch block, n (%)
Left ventricular systolic function
Normal (50%), n (%)
Mild (40e49%), n (%)
Moderate (30e39%), n (%)
Severe (<30%), n (%)
Coronary angiogram (n ¼ 749)
Single vessel disease, n (%)
Double vessel disease, n (%)
Left main or triple vessel disease, n (%)
Nonsigniﬁcant coronary artery disease, n (%)
Normal, n (%)

Total,
2609

PP  50,
1360 (52.1%)

PP > 50,
1249 (47.9%)

P-value

128.7 ± 31.3
74.1 ± 17.9
88.8 ± 21.0

108.9 ± 18.0
70.5 ± 15.6
89.4 ± 20.8

150.2 ± 28.5
78.0 ± 19.3
88.2 ± 21.2

<0.001
<0.001
0.134

389 (15.0)
305 (11.7)

225 (16.6)
150 (11.0)

164 (13.1)
155 (12.4)

0.013
0.273

341 (13.7)
334 (13.4)
632 (25.3)
1187 (47.6)

91 (6.9)
117 (8.9)
320 (24.3)
788 (59.9)

250
217
312
399

<0.001

105 (13.7)
116 (15.2)
263 (34.4)
82 (10.7)
183 (24.0)

55 (12.7)
55 (12.7)
146 (33.6)
45 (10.4)
123 (28.3)

50 (15.2)
61 (18.5)
117 (35.5)
37 (11.2)
60 (18.2)

3. Results
3.1. Baseline Demographics
Generally, patients with low PP were younger and
had greater male predominance. Further, they were
more likely to have a previous history of HF, and
less likely to be diabetic, hypertensive, or dyslipidemic. On the other hand, the high PP patients had
higher rates of previous atherosclerotic events,
anemia, chronic renal insufﬁciency, and chronic
lung diseases (P < 0.05 for all comparisons) (Table
1). Patients with elevated PP had a signiﬁcantly
higher prevalence of hypertensive cardiomyopathy
and lower rates of idiopathic dilated cardiomyopathy (P < 0.001 for group comparison). Uncontrolled
hypertension was the main exacerbating factor for
AHF in the high PP group, while medication and
dietary noncompliance were higher in the opposing
group (P < 0.001 for all comparisons) (Table 2). The
high PP group had higher average SBP and DBP
values (150.2 vs. 108.9 mmHg; P < 0.001, and 78.0 vs.
70.5 mmHg; P < 0.001, respectively) and lower rates
of severely reduced EF (P < 0.001 for group comparison). Among patients undergoing coronary
angiogram in the same admission (n ¼ 749), normal
studies were more often reported in the low PP
group (P ¼ 0.001) (Table 3). Fig. 1 demonstrates all
differences in medication use between the groups.
There was a trend of higher use of statins and lower
use of aldosterone antagonists in the high PP group
on admission and at discharge (P < 0.01 for all
comparisons). In addition, the requirement of
inotropic support with dobutamine and dopamine
was greater in patients with low PP, while the need

(21.2)
(18.4)
(26.5)
(33.9)

0.324
0.027
0.601
0.709
0.001

for nitroglycerin infusions was higher in the other
group (P < 0.001 for all comparisons).
3.2. Primary Endpoints
In crude analysis, patients having low PP experienced higher rates of hospital recurrence of HF,
shock state, and ventricular arrhythmias (P < 0.001
for all comparisons), as well as higher requirements
for intra-aortic balloon pumps, implantable cardioverter deﬁbrillators, and cardiac resynchronization therapy (P < 0.05 for all comparisons).
Furthermore, they had higher rates of hospital and
thirty-day mortality (7.9 vs. 5.0%; P ¼ 0.004, and 9.6
vs. 6.6%; P ¼ 0.005, respectively), but not after one,
two, or three years (Table 4). In univariate regression analysis, low PP was associated with greater
short-term mortality in the overall population, and
short-term and two-year mortality in HFrEF.
Furthermore, initial multivariate analyses revealed
PP was predictive of both short- and long-term
mortality in the overall population and HFrEF, but
not HFpEF. However, the stepwise introduction of
SBP, but not DBP, to adjustment models eliminated
this mortality association, but showed an independent inverse correlation with long-term mortality in
HFpEF only (OR ¼ 0.43; 95% CI 0.24, 0.78; P ¼ 0.005
and OR ¼ 0.49; 95% CI 0.28, 0.88; P ¼ 0.016 for twoand three-year mortality, respectively) (Table 5 and
Fig. 2). Of note, a subgroup analysis on HFpEF patients only showed higher rates of diabetes mellitus,
hypertension, dyslipidemia, and chronic renal
insufﬁciency in the high PP group (P < 0.001 for all
comparisons) (See online supplementary material,
Table S1).
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Fig. 1. Differences in evidence-based medical therapies used before admission (A), during hospital stay (B), and at discharge (C) based on pulse
pressure median value. Abbreviations: AA: aldosterone antagonists, ACEI: angiotensin converting enzyme inhibitors, ARB: angiotensin receptor
blockers, BB: b-blockers, PP: pulse pressure. * P-value < 0.05. ** P-value < 0.01. *** P-value < 0.001.
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Table 4. Adverse hospital events and short- and long-term mortality rates of all acute heart failure patients based on pulse pressure median value.

Hospital complications
Recurrent heart failure, n (%)
Sepsis, n (%)
Shock, n (%)
Ventricular arrhythmias, n (%)
Atrial ﬁbrillation requiring therapy, n (%)
Major bleeding, n (%)
Transient ischemic attack/stroke, n (%)
Hospital procedures
Dialysis, n (%)
Ventilation, n (%)
Intra-aortic balloon pumps, n (%)
Pacing, n (%)
Hospital implantable cardioverter deﬁbrillator, n (%)
Hospital cardiac resynchronization therapy, n (%)
All-cause mortality
Hospital mortality
Thirty-day mortality
One-year mortality
Two-year mortality
Three-year mortality

Total,
2609

PP  50,
1360 (52.1%)

PP > 50,
1249 (47.9%)

P-value

816 (31.3)
196 (7.5)
228 (8.7)
110 (4.2)
156 (6.0)
38 (1.5)
48 (1.8)

493 (35.4)
109 (7.8)
152 (10.9)
86 (6.2)
93 (6.7)
21 (1.5)
29 (2.1)

323 (26.5)
87 (7.1)
76 (6.2)
24 (2.0)
63 (5.2)
17 (1.4)
19 (1.6)

<0.001
0.503
<0.001
<0.001
0.104
0.808
0.320

125 (4.8)
289 (11.1)
86 (3.3)
36 (1.4)
150 (5.8)
68 (2.6)

69 (5.0)
161 (11.6)
66 (4.7)
23 (1.6)
110 (7.9)
45 (3.2)

56 (4.6)
128 (10.5)
20 (1.6)
13 (1.1)
40 (3.3)
23 (1.9)

0.665
0.387
<0.001
0.200
<0.001
0.031

170
212
509
615
635

107
130
279
335
343

63 (5.0)
82 (6.6)
230 (18.4)
280 (22.4)
292 (23.4)

0.004
0.005
0.177
0.183
0.274

4. Discussion
In this report, we examined the prognostic value of
PP in patients admitted with AHF. PP, when
measured peripherally via conventional BP measurement devices on hospital arrival, was not an independent predictor of mortality in our overall
population. However, the relationship between PP
and HF outcomes represents a complex interaction
between several factors, such as the HF phenotype,
original
BP
components,
and
coexistent

(6.5)
(8.1)
(19.5)
(23.6)
(24.4)

(7.9)
(9.6)
(20.5)
(24.7)
(25.2)

comorbidities. Our data showed that the predictive
value of low PP for mortality in HFrEF was dependent
on SBP, while long-term mortality rates correlated
independently with elevated baseline PP in HFpEF.
PP was examined in multiple heterogeneous HF
populations with various conclusions (Table 6). Low
PP in chronic symptomatic HFrEF was consistently
shown to correlate with decreased long-term survival
[8e14]. Nonetheless, there was a reverse pattern seen
in asymptomatic HF patients, as reported by the

Table 5. Crude and adjusted odds ratio and 95% conﬁdence interval for mortality in acute heart failure based on pulse pressure median value
(50 mmHg).
Crude OR (95% CI)
Overall
Hospital mortality
Thirty-day mortality
One-year mortality
Two-year mortality
Three-year mortality
Ejection fraction < 40%,
Hospital mortality
Thirty-day mortality
One-year mortality
Two-year mortality
Three-year mortality
Ejection fraction > 40%,
Hospital mortality
Thirty-day mortality
One-year mortality
Two-year mortality
Three-year mortality

1.61 (1.17,
1.51 (1.13,
1.14 (0.94,
1.13 (0.94,
1.11 (0.92,
N ¼ 1819
1.81 (1.19,
1.69 (1.17,
1.26 (0.98,
1.29 (1.02,
1.24 (0.99,
N ¼ 675
1.28 (0.65,
1.18 (0.63,
0.84 (0.55,
0.70 (0.46,
0.69 (0.46,

P-value

Adjusted OR (95% CI)

2.22)
2.01)
1.39)
1.36)
1.32)

0.004
0.005
0.177
0.184
0.274

1.86
1.83
1.46
1.44
1.42

(1.29,
(1.32,
(1.17,
(1.17,
(1.15,

2.74)
2.45)
1.60)
1.61)
1.55)

0.005
0.006
0.067
0.030
0.057

2.06
1.93
1.51
1.62
1.59

2.51)
2.20)
1.30)
1.05)
1.03)

0.480
0.613
0.445
0.087
0.072

1.61
1.59
1.06
0.81
0.82

a

b

P-value

Adjusted OR (95% CI)

P-value

2.67)
2.54)
1.83)
1.78)
1.75)

0.001
<0.001
0.001
0.001
0.001

0.86
1.03
0.96
0.96
0.98

(0.54,
(0.68,
(0.72,
(0.73,
(0.75,

1.37)
1.56)
1.28)
1.26)
1.28)

0.515
0.908
0.783
0.772
0.854

(1.33,
(1.31,
(1.16,
(1.26,
(1.24,

3.19)
2.84)
1.97)
2.08)
2.03)

0.001
0.001
0.002
<0.001
<0.001

1.13
1.33
1.11
1.19
1.16

(0.65,
(0.82,
(0.80,
(0.87,
(0.85,

1.95)
2.16)
1.56)
1.63)
1.58)

0.675
0.251
0.531
0.281
0.353

(0.76,
(0.79,
(0.64,
(0.50,
(0.51,

3.41)
3.20)
1.76)
1.31)
1.32)

0.212
0.191
0.829
0.388
0.414

0.44
0.49
0.55
0.43
0.49

(0.16,
(0.20,
(0.29,
(0.24,
(0.28,

1.16)
1.20)
1.02)
0.78)
0.88)

0.095
0.119
0.058
0.005
0.016

a
Adjusted for age, gender, body mass index, diabetes mellitus, smoking, hypertension, dyslipidemia, history of heart failure, anemia,
heart failure etiology, heart rate, and estimated glomerular ﬁltration rate.
b
Adjusted for age, gender, body mass index, diabetes mellitus, smoking, hypertension, dyslipidemia, history of heart failure, anemia,
heart failure etiology, heart rate, estimated glomerular ﬁltration rate, and systolic blood pressure.

Table 6. Comparison of populations and outcomes between all studies examining pulse pressure in heart failure.
#

Author

Study name

N

Population

Follow-up

EF

Conclusions

Notes

1

Aljohar, 2020

HEARTS

2609

Acute HF

36 months

All

e

2

Laskey, 20169

GWTG-HF

40,421

Acute HF

12 months

All

3

Jackson, 20158

MAGGIC

25,465

Acute and chronic HF

36 months

All

4

Teng, 201811

SwedeHF

36,770

Acute and chronic HF

12 months

All

5

Voors, 200512

PRIME

1901

11 months

<35%

6

Petrie, 201213

CAPRICORN

1955

Chronic symptomatic
HFrEF
EF < 40% post-ACS

15 months

<40%

7

Regnault, 201414

EPHESUS

6613

EF < 40% post-ACS

16 months

<40%

8

Mitchell, 199716

SAVE

2231

Asymptomatic HFrEF
post-ACS

42 months

<40%

9

Domanski, 199915

SOLVD

6781

Chronic HFrEF; 60%
asymptomatic

40 months

<35%

10

Aronson, 200417

VMAC

489

Acute HF

6 months

<35%

HFrEF: Low PP showed trend towards
short-term mortality.
HFpEF: High PP associated with longterm mortality.
HFrEF: Low and high PP both
associated with mortality; nadir of
50 mmHg.
HFpEF: High PP associated with
mortality if SBP >140 mmHg.
HFrEF: Low PP (<53 mmHg) associated
with mortality.
HFpEF: No association between
mortality and PP.
HFrEF: Low PP (<40 mmHg) associated
with mortality.
HFmrEF: Trend towards higher
mortality with PP > 70 mmHg.
HFpEF: Low PP associated with
mortality & trend towards higher
mortality with PP > 75 mmHg.
Low PP (<45 mmHg) associated with
mortality.
Low PP associated with mortality in Killip
II-IV (17% increase in mortality for every
10-mmHg incremental decrease).
Low PP associated with mortality (5%
increase in mortality for every 5-mmHg
incremental decrease).
High PP associated with mortality (8%
increase in mortality for every 10-mmHg
incremental increase).
High PP associated with mortality (5%
increase in mortality for every 10-mmHg
incremental increase).
Low PP (<43 mmHg) associated with
mortality.

PP obtained at discharge.

In-hospital deaths excluded.

e
Comparison based on Killip
classification.
PP impacted on mortality
more than SBP and MAP.
e

Decreased MAP impacted
more on poor outcomes.

JOURNAL OF THE SAUDI HEART ASSOCIATION 2020;32:263e273

Subgroup analysis (acute vs.
chronic) showed no
interaction.

SBP <90 mmHg excluded.

Abbreviations: ACS: acute coronary syndromes, CAPRICORN: Carvedilol Post Infarct Survival Control in LV Dysfunction, EPHESUS: Eplerenone PosteAcute Myocardial Infarction
Heart Failure Efﬁcacy and Survival Study, GWTG-HF: Get with the Guidelines-Heart Failure program, HEARTS: Heart Function Assessment Registry Trial in Saudi Arabia, HF: heart
failure, HFmrEF: heart failure with mid-range ejection fraction, HFpEF: heart failure with preserved ejection fraction, HFrEF: heart failure with reduced ejection fraction, MAGGIC:
Meta-Analysis Global Group in Chronic Heart Failure, MAP: mean arterial pressure, PP: pulse pressure, PRIME: Prospective Randomized study of Ibopamine on Mortality and
Efﬁcacy, SAVE: Survival and Ventricular Enlargement study, SBP: systolic blood pressure, SOLVD: Study of Left Ventricular Dysfunction, SwedeHF: The Swedish Heart Failure
Registry, VMAC: Vasodilation in the Management of Acute Congestive study.
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SOLVD (Study of Left Ventricular Dysfunction) [15]
and SAVE (Survival and Ventricular Enlargement)
[16] investigators. The exact explanation for these
discrepant observations is not clear, although the
presence of symptoms may be an indicator of an
advanced state of HF with low cardiac output and
hence lower PP. Few studies have looked into the association between PP and long-term outcomes in patients hospitalized for AHF and reported ﬁndings in
line with the pattern seen with chronic symptomatic
HFrEF [8],[9],[11],[17]. To the best of our knowledge,
this is the ﬁrst report to comment on admission PP and
its correlation with hospital mortality. Our regression
models revealed the predictive power of PP in HFrEF
was not totally independent from original BP components, speciﬁcally SBP. The discrepancies between
our study and others is likely due to several factors.
Our patient population has a different ethnic background and has a younger mean age. Additionally,
there were methodological differences that render our
cohort incomparable, such as measuring PP at
discharge [9], excluding in-hospital deaths [11], and
using different PP cutoffs. Finally, the overall heterogeneity in HF syndromes may have also contributed to
these differences.
Physiologically, PP is thought to be a measure of
both stroke volume and vascular stiffness. In early
systole, the ejected blood from the LV travels across
the arterial tree from large and elastic to narrow and
muscular vessels. This is followed by a reﬂected wave
against the LV during late systole, mandating extra
force generation (referred to as augmentation pressure) [21]. In advanced HF, the LV fails to exert this
extra pressure, explaining why low PP correlates with
poor outcomes in ambulatory HFrEF. Notwithstanding, the rapid disturbance of hemodynamics in a
decompensated state and the emergent use of vasoactive and inotropic agents may have diminished the
prognostic impact of PP. Nonetheless, we speculate it
may have independently predicted hospital mortality,
had values lower than 50 mmHg been tested in patients with worse LV dysfunction.
We observed greater long-term mortality rates in
patients with HFpEF and elevated baseline PP, in
agreement with others [9]. Our subgroup analysis of
HFpEF patients showed that higher PP was signiﬁcantly associated with hypertension, diabetes mellitus, dyslipidemia, and chronic renal insufﬁciency,
all of which are known to be associated with accelerated atherosclerosis and worse outcomes. Arteriosclerosis plays an important role in the
pathophysiology and prognosis of HF. In one HF
trial, a subgroup of patients underwent measurements of pulse wave velocity, a direct indicator of
vascular stiffness, with elevated readings at baseline

Fig. 2. Kaplan-Meier plot for all-cause mortality in all acute heart
failure patients (A), heart failure with reduced ejection fraction (B), and
heart failure with preserved ejection fraction (C) based on pulse pressure
median value. Abbreviations: PP: pulse pressure.

predicting decreased survival during prolonged
follow-up [14]. Nonetheless, it is worthwhile to
explore other potential confounders in future
research, which may have an inﬂuence on HF circulatory hemodynamics, such as advanced age [22],
heart rate [23], LV end-diastolic volume and mass
[24],[25], and anti-HF medications [26].
Central BP is the actual pressure exerted against the
LV and the true determinant of renal and brain
perfusion [27]. Hence, its predictability for future risk
of major adverse cardiac events and end-organ damage is more accurate [24],[28]. How reliable estimating
central PP from peripheral arteries is debatable [29].
The elasticity of peripheral vessels is relatively
reduced [30]. PP ampliﬁcation is a compensatory
mechanism that exaggerates the forward ﬂow of blood
through these narrower lumens and may overestimate the actual central PP [21]. However, this difference diminishes with aging, as the aorta and its
great branches gradually lose elasticity [31],[32].
Several commercial devices noninvasively measure
central PP, but they lack standardization, providing
ineffective alternatives to invasive methods.
Our study suffers from several limitations. Our
classiﬁcation of HF was based on the guidelines
published during the enrollment period, which did
not include the newly-deﬁned HF with mid-range
EF as a discrete entity. There was no predeﬁned
standard method of BP measurement during
enrollment of the study cohort. Although this may
generate inaccurate conclusions, it reﬂects ‘real-life’
practice and eases the generalizability of our ﬁndings. We did not record readmission rates and
actual cause of death during the follow-up period,
which are considered standard primary endpoints
in large-scale registries in cardiovascular medicine.
Our sample size, although large and representative,
was not enough to study PP in quartiles or quintiles,
or within different strata of SBP ranges.

5. Conclusion
PP is a noninvasive and inexpensive tool that is
readily available. In this study, it did not independently correlate with morbidity and mortality in the
overall AHF population. However, its prognostic value
in this domain seems to be a function of phenotype.
Whereas its predictive value in HFrEF was dependent
on SBP, elevated baseline PP independently correlated
with decreased long-term survival in HFpEF.
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Supplementary Material
Table S1. Baseline characteristics of heart failure with preserved ejection fraction patients based on pulse pressure median value.

Age, mean ± SD
Male, n (%)
Body mass index, mean ± SD
Diabetes mellitus, n (%)
Smoker/Ex-smoker, n (%)
Hypertension, n (%)
Dyslipidemia, n (%)
Heart failure, n (%)
Ischemic heart disease, n (%)
Anemia, n (%)
Chronic renal insufﬁciency, n (%)
Chronic lung disease, n (%)

Total,
675 (25.8%)

PP  50,
467 (69.2%)

PP > 50,
208 (30.8%)

P-value

64.3 ± 13.9
323 (47.9)
31.5 ± 8.3
457 (67.8)
153 (22.7)
527 (78.3)
273 (43.7)
389 (58.0)
312 (46.6)
350 (52.2)
208 (30.9)
71 (10.6)

61.9 ± 16.7
102 (49.0)
29.8 ± 7.3
106 (51.2)
54 (26.0)
127 (61.4)
61 (32.8)
115 (55.6)
83 (40.3)
93 (45.1)
45 (21.6)
16 (7.8)

65.4 ± 12.3
221 (47.3)
32.2 ± 8.6
351 (75.2)
99 (21.2)
400 (85.8)
211 (48.4)
274 (59.1)
229 (49.5)
257 (55.4)
163 (35.0)
55 (11.9)

0.007
0.680
<0.001
<0.001
0.172
<0.001
<0.001
0.397
0.028
0.014
0.001
0.111
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